Biotech Stocks Drop Amidst Failed Bone Disease Drug Trials
Ultragenyx Pharmaceutical's experimental drug setrusumab for osteogenesis imperfecta failed to reduce fracture rates in late-stage studies, leading to a 43.5% drop in its stock price and potential discontinuation of the program, despite improvements in bone mineral density.